Quantitative assessment of the effects of sulfamethoxazole on Toxoplasma gondii loads in susceptible WT C57BL/6 mice as an immunocompetent host model.

[1]  Ayaka Tanaka,et al.  Metabolic activation of hepatotoxic drug (benzbromarone) induced mitochondrial membrane permeability transition. , 2015, Toxicology and applied pharmacology.

[2]  J. Garweg,et al.  Therapy for Ocular Toxoplasmosis – The Future , 2013, Ocular immunology and inflammation.

[3]  R. Lira,et al.  Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. , 2013, American journal of ophthalmology.

[4]  A. Upton,et al.  Neuropsychiatric symptoms are common in immunocompetent adult patients with Toxoplasma gondii acute lymphadenitis , 2013, Scandinavian journal of infectious diseases.

[5]  K. Severing,et al.  Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis? , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[6]  Sonia Pereyra,et al.  Disseminated toxoplasmosis in an immunocompetent patient from Peruvian Amazon. , 2010, Revista do Instituto de Medicina Tropical de Sao Paulo.

[7]  M. Demar,et al.  Severe Acquired Toxoplasmosis Caused by Wild Cycle of Toxoplasma gondii, French Guiana , 2009, Emerging infectious diseases.

[8]  M. Habek,et al.  Unusual cause of dementia in an immunocompetent host: toxoplasmic encephalitis , 2009, Neurological Sciences.

[9]  A. Crisanti,et al.  Temporal and Spatial Distribution of Toxoplasma gondii Differentiation into Bradyzoites and Tissue Cyst Formation In Vivo , 2008, Infection and Immunity.

[10]  C. Jost,et al.  The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8−/− mice , 2007, Parasitology Research.

[11]  H. F. de Andrade,et al.  Toxoplasma gondii pneumonia in immunocompetent subjects: case report and review. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Y. Iwakura,et al.  Evaluation of the Effects of Sulfamethoxazole on Toxoplasma gondii Loads and Stage Conversion in IFN‐γ Knockout Mice Using QC‐PCR , 2004, Microbiology and immunology.

[13]  B. Horta,et al.  The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. , 2002, American journal of ophthalmology.

[14]  R. Lyons,et al.  Toxoplasma gondii tachyzoite-bradyzoite interconversion. , 2002, Trends in parasitology.

[15]  M. Chen,et al.  Organ Infectivity of Toxoplasma gondii in Interferon-γ Knockout Mice , 2001 .

[16]  S. Parmley,et al.  Induction of tumor necrosis factor-α and inducible nitric oxide synthase fails to prevent toxoplasmic encephalitis in the absence of interferon-γ in genetically resistant BALB/c mice. , 2000 .

[17]  G. Pizzolato,et al.  Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. , 1999, International journal of antimicrobial agents.

[18]  J. Dubey,et al.  Advances in the life cycle of Toxoplasma gondii. , 1998, International journal for parasitology.

[19]  S. Sekiya,et al.  Kinetics in parasite abundance in susceptible and resistant mice infected with an avirulent strain of Toxoplasma gondii by using quantitative competitive PCR. , 1997, The Journal of parasitology.

[20]  J. Lo-Guidice,et al.  NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. , 1997, Pharmacogenetics.

[21]  W. Melchers,et al.  Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. , 1996, The Journal of antimicrobial chemotherapy.

[22]  P T de Jong,et al.  Therapy of ocular toxoplasmosis. , 1993, International ophthalmology.

[23]  K. Norose,et al.  Effects of Sulfamethoxazole on Murine Ocular Toxoplasmosis in Interferon-γ Knockout Mice , 2006 .

[24]  G. Holland.  Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. , 2004, American journal of ophthalmology.